The antibody cancer drug market is currently at $130 billion expected to grow to $280 billion by 2032. While antibodies are remarkable drugs, only a tiny proportion of the dose makes it into the tumour. Creasallis has developed the CreaTap engineering biology solution to improve how antibodies penetrate solid tumours. Improving the penetration by as little as twofold would have a large impact on patient drug safety, dosage and treatment effectiveness. CreaTap can be incorporated into any oncology-based antibody or antibody-like drug with no impact on the drugs stability, manufacturability or binding.
Zahra Jawad is the founder and the inventor of the CreaTap concept. She is CEO of the company and is currently responsible for the day to day running of the business, is on the board of investors and provides strategic scientific direction. She is finding this role challenging at this stage of the company’s development.
She recognises that the Shott Scale Up Accelerator can help her realise the strong set of values and vision she started out with. She acknowledges that she has ‘struggled to build the culture I had the vision for and to implement it’. She sees the coaching and peer to peer experiences available through the Shott Scale Up Accelerator as a key element to help building the team.
While the product is still in R&D and Creasallis are looking to find partners to help test their technology more than selling in markets. However, Zahra recognises the next 12 months as a crucial scale up phase that the support from the Shott Scale Up Accelerator will be crucial for. She sees their biggest value add is to the antibody drug conjugates market, which is currently $8.7 billion and expected to grow to $83 billion by 2032.
